Public Disclosure of the Filing of New Drug and Therapeutic Biologics Applications With the US Food and Drug Administration

Ítems similars

• Contents of US Food and Drug Administration Refuse-to-File Letters for New Drug Applications and Efficacy Supplements and Their Public Disclosure by Applicants
  per: Chahal, Harinder Singh, et al.
  Publicat: (2021)
• Impact of the US Food and Drug Administration registration of antiretroviral drugs on global access to HIV treatment
  per: Chahal, Harinder Singh, et al.
  Publicat: (2018)
• The US Food and Drug Administration's tentative approval process and the global fight against HIV
  per: Chahal, Harinder Singh, et al.
  Publicat: (2017)
• An Evaluation of US Food and Drug Administration’s Program to Register HIV Drugs for Use in Resource-Constrained Settings
  per: Chahal, Harinder Singh, et al.
  Publicat: (2019)
• Publication and Reporting of the Results of Postmarket Studies for Drugs Required by the US Food and Drug Administration, 2009 to 2013
  per: Cruz, Marisa L., et al.
  Publicat: (2017)